MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1806105

Медицинская библиотека · Frontiers in immunology · 2026

The prognostic value of the lung immune prognostic index in patients with urological cancers: a systematic review and meta-analysis.

Lyu Zhaojie, Xiao Yuhan, Wang Jie, Wu Ruicheng, Yoo Koo Han, Wei Wuran, Zhang Qi, Xie Yandong, Feng Dechao

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

The Lung Immune Prognostic Index (LIPI), derived from the derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase, integrates systemic inflammation and tumour burden. Its prognostic utility in urological malignancies has not been comprehensively quantified.

METHODS

We conducted a systematic review and meta-analysis in accordance with PRISMA and a prospectively registered protocol. PubMed, Embase, and the Cochrane Library were searched through October 2025. Eligible cohort studies or trials evaluated associations between LIPI categories (good/intermediate/poor) and survival outcomes in renal cell carcinoma, urothelial carcinoma, and prostate cancer. Random-effects models were fitted using REML with Hartung-Knapp adjustment. When hazard ratios (HRs) were not directly reported, we reconstructed pseudo-individual patient data from Kaplan-Meier curves to estimate HRs.

RESULTS

Thirteen studies (19 independent cohorts; 5,304 patients) were included. Compared with good LIPI, intermediate LIPI was associated with worse overall survival (OS) (HR 1.73, 95% CI 1.52-1.98) and shorter progression-free survival (PFS; including disease-free survival after surgery where applicable) (HR 1.39, 95% CI 1.13-1.71). Poor LIPI showed a stronger association with inferior OS (HR 3.73, 95% CI 2.95-4.71) and PFS (HR 2.69, 95% CI 1.96-3.70). Prognostic gradients were generally consistent across tumour types and treatment settings, including immune checkpoint inhibitor-treated cohorts.

CONCLUSIONS

LIPI is a readily available biomarker that provides robust risk stratification across major urological cancers and may support treatment planning and trial stratification.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251235082, identifier CRD420251235082.

Для цитирования: Lyu Zhaojie, Xiao Yuhan, Wang Jie, Wu Ruicheng, Yoo Koo Han, Wei Wuran, Zhang Qi, Xie Yandong, Feng Dechao. The prognostic value of the lung immune prognostic index in patients with urological cancers: a systematic review and meta-analysis.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1806105.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.